Hoth Therapeutics Inc
NASDAQ:HOTH
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.693
2.28
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Hoth Therapeutics Inc
Free Cash Flow
Hoth Therapeutics Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Hoth Therapeutics Inc
NASDAQ:HOTH
|
Free Cash Flow
-$10m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Free Cash Flow
$19.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Free Cash Flow
$15.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
31%
|
|
|
Pfizer Inc
NYSE:PFE
|
Free Cash Flow
$10.4B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Free Cash Flow
$13B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
14%
|
CAGR 10-Years
8%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Free Cash Flow
$6.4B
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
14%
|
|
Hoth Therapeutics Inc
Glance View
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2019-02-15. The firm is also focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer; a treatment for mast-cell derived cancers and anaphylaxis, and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases. The Company’s preclinical assets for atopic dermatitis; treatment for asthma and allergies using inhalational administration; a treatment for lung diseases resulting from bacterial infections, and treatment for inflammatory bowel diseases. The firm is also developing a diagnostic device via a mobile device. Its primary development products include HT-001, HT-KIT and HT-ALZ. Its preclinical development products include HT-003, HT-004, HT-006 and HT-002. The company is also developing a COVID-19 treatment as well as a diagnostic device for the detection of viruses via a mobile device.
See Also
What is Hoth Therapeutics Inc's Free Cash Flow?
Free Cash Flow
-10m
USD
Based on the financial report for Sep 30, 2025, Hoth Therapeutics Inc's Free Cash Flow amounts to -10m USD.
What is Hoth Therapeutics Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-7%
Over the last year, the Free Cash Flow growth was -25%. The average annual Free Cash Flow growth rates for Hoth Therapeutics Inc have been 2% over the past three years , -7% over the past five years .